<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04813016</url>
  </required_header>
  <id_info>
    <org_study_id>intraperitoneal analgesia</org_study_id>
    <nct_id>NCT04813016</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Tramadol Versus Dexmedetomedine for Analgesia After Abdominal Laparoscopic Cancer Surgeries</brief_title>
  <official_title>Comparative Study Between Intraperitoneal Administration of Either Bupivacaine and Tramadol Versus Bupivacaine and Dexmedetomedine for Analgesia After Abdominal Laparoscopic Cancer Surgeries. A Prospective Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple modalities for postoperative analgesia after laparoscopic procedures has been used,&#xD;
      of them intraperitoneal route (IP) was used to decrease the analgesic requirements. Both&#xD;
      early and late bupivacaine and tramadol versus bupivacaine and dexmedetomedine will be tried&#xD;
      to choose which is having a better analgesic profile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently laparoscopic procedures have become popular and familiar to both surgeons and&#xD;
      anesthetists. They have many advantages such as rapid postoperative recovery, low&#xD;
      postoperative complication rates, early mobilization, and early home discharge; consequently&#xD;
      reduce hospital stay and costs. Although previous studies have been shown that laparoscopy is&#xD;
      associated with less pain than laparotomy, it is not totally pain free. Some laparoscopic&#xD;
      procedures for abdominal cancer surgeries has shown that there may be more intense pain and&#xD;
      greater analgesic requirements in the immediate postoperative period than after open&#xD;
      laparotomy.&#xD;
&#xD;
      Thoroughly understanding the difference of pain generators in laparotomy than in laparoscopy&#xD;
      gave some ideas helping in the control of each of them. While laparotomy results mainly in&#xD;
      parietal pain, visceral pain remains predominantly in patients after laparoscopic surgeries&#xD;
      resulting from the stretching of intra-abdominal cavity, peritoneal inflammation and phrenic&#xD;
      nerve irritation caused by residual carbon dioxide in the peritoneal cavity resulting in&#xD;
      postoperative abdominal and shoulder pain after laparoscopy. Hence, Intraperitoneal (IP)&#xD;
      administration of some drugs can be effective for pain relief after laparoscopic surgery. The&#xD;
      results have been variable as the published studies are heterogeneous and often lack&#xD;
      appropriate controls. For that, no definitive conclusion can yet be made regarding its value&#xD;
      and effectiveness.&#xD;
&#xD;
      The α2-adrenergic agonist provides excellent sedation, anxiolysis, analgesia and&#xD;
      sympatholysis. Of them, dexmedetomidine has become one of the frequently used drugs in&#xD;
      anaesthesia aiming to its hemodynamic, sedative, anxiolytic, analgesic, neuroprotective and&#xD;
      anaesthetic sparing effect. In addition, the high selectivity of dexmedetomidine to α2-&#xD;
      receptors favored its widespread use in regional anaesthesia practice and local nerve blocks&#xD;
      techniques.&#xD;
&#xD;
      As noradrenergic neurons descending through the dorso-lateral funiculus from the brainstem to&#xD;
      the dorsal horn significantly contribute in the modulation of pain by controlling impulse&#xD;
      transmission (descending inhibitory pathway). Adrenergic agonists, such as dexmedetomedine,&#xD;
      possess significant antinociceptive activity by a central action on the brainstem and a&#xD;
      spinal action on the substantia gelatinosa of the dorsal horn.&#xD;
&#xD;
      Tramadol is a synthetic opioid pain medication used to treat moderate to moderately severe&#xD;
      pain. It exerts its analgesic effects through a variety of different targets on the&#xD;
      noradrenergic, serotoninergic and opioid receptors systems. It also exists as a racemic&#xD;
      mixture, the positive enantiomer inhibits serotonin reuptake while the negative enantiomer&#xD;
      inhibits noradrenaline re-uptake, by binding to and blocking the transporters. Finally,&#xD;
      tramadol has also been shown to act as a serotonin releasing agent. Both enantiomers of&#xD;
      tramadol are agonists of the μ-opioid receptor and its M1 metabolite, O-demethylate, which is&#xD;
      also a μ-opioid receptor agonist but is 6 times more potent than tramadol itself. All these&#xD;
      effects work synergistically to induce analgesia.&#xD;
&#xD;
      The aim of this study is to examine and compare the effect of both early and late&#xD;
      intraperitoneal bupivacaine/tramadol and bupivacaine/dexmedetomedine analgesia on the&#xD;
      effectiveness of postoperative analgesia and the requirement of postoperative rescue&#xD;
      analgesics after laparoscopic surgery for abdominal cancer surgeries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The degree of pain</measure>
    <time_frame>24 hours</time_frame>
    <description>measurement of VAS</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Early tramal/bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received 50 ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% immediately before creation of a pneumoperitoneum and placement of the first two trocars before starting the surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late tramal/bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received 50ml of isotonic aqueous solution (PH 7.45) of tramadol 150mg mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early dexmedetomedine/bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% before creation of a pneumoperitoneum and placement of the first two trocars before the start of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late dexmedetomedine/bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received 50ml of isotonic aqueous solution (PH 7.45) of dexmedetomedine(1µ/kg) mixed with bupivacaine 0.25% after completion of surgery and before trocars removal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramal 1</intervention_name>
    <description>Early intraperitoneal injection of tramal and bupivacaine</description>
    <arm_group_label>Early dexmedetomedine/bupivacaine</arm_group_label>
    <arm_group_label>Late dexmedetomedine/bupivacaine</arm_group_label>
    <arm_group_label>Late tramal/bupivacaine</arm_group_label>
    <other_name>Early tramal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramal 2</intervention_name>
    <description>Late intraperitoneal injection of tramal and bupivacaine</description>
    <arm_group_label>Early dexmedetomedine/bupivacaine</arm_group_label>
    <arm_group_label>Early tramal/bupivacaine</arm_group_label>
    <arm_group_label>Late dexmedetomedine/bupivacaine</arm_group_label>
    <other_name>Late tramal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine 1</intervention_name>
    <description>Early intraperitoneal injection of dexmedetomidine and bupivacaine</description>
    <arm_group_label>Early tramal/bupivacaine</arm_group_label>
    <arm_group_label>Late dexmedetomedine/bupivacaine</arm_group_label>
    <arm_group_label>Late tramal/bupivacaine</arm_group_label>
    <other_name>Early Dexmedetomidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine 2</intervention_name>
    <description>Late intraperitoneal injection of dexmedetomedine and bupivacaine</description>
    <arm_group_label>Early dexmedetomedine/bupivacaine</arm_group_label>
    <arm_group_label>Early tramal/bupivacaine</arm_group_label>
    <arm_group_label>Late tramal/bupivacaine</arm_group_label>
    <other_name>Late Dexmedetomidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA II or III.&#xD;
&#xD;
          -  Age 18 to 65 years.&#xD;
&#xD;
          -  Elective surgeries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severe hepatic (more than child c), renal (known CKD)and cardiac (known&#xD;
             IHD) troubles.&#xD;
&#xD;
          -  Patients with extensive intraperitoneal adhesions.&#xD;
&#xD;
          -  Patients with a history of drug or analgesic abuse.&#xD;
&#xD;
          -  Known drug allergy or indigestion.&#xD;
&#xD;
          -  Intraoperative lavage of more than 500ml.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehab H Gendy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor of Anesthesia, intensive care and pain releif</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ehab H Gendy, MD</last_name>
    <phone>+201222438820</phone>
    <email>ehabhanafy2006@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ehab H Shaker, MD</last_name>
      <phone>01222438820</phone>
      <email>ehabhanafy2006@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://www.saudija.org/article.asp?issn=1658-354X;year=2018;volume=12;issue=3;spage=399;epage=405;aulast=Elnabtity</url>
    <description>Intraperitoneal dexmedetomidine as an adjuvant to bupivacaine for postoperative pain</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 20, 2021</study_first_submitted>
  <study_first_submitted_qc>March 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Ehab Hanafy Shaker</investigator_full_name>
    <investigator_title>Assistant professor of Anesthesia, intensive care and pain releif</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>After manuscript approval and acceptance by a journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

